Lives unaffected by cystic fibrosis


Back to the Drug Development Pipeline

VX-445 + tezacaftor + ivacaftor

Phase Three

Phase Three

Therapeutic Approach

Restore CFTR Function

This program is testing VX-445 in combination with tezacaftor and ivacaftor. VX-445 and tezacaftor (VX-661) are new CFTR correctors. Correctors are drugs designed to fix the defective CFTR protein so that it can move to the proper place on the cell surface. Once CFTR protein reaches the cell surface, ivacaftor helps facilitate the opening of the chloride channel to allow chloride and sodium (salt) to move in and out of the cell. 


A phase 1 and 2 study to test the safety and tolerability of VX-445 is underway.


This program is sponsored by Vertex Pharmaceuticals and partially funded by Cystic Fibrosis Foundation Therapeutics (CFFT). This program is being conducted within CFFT’s Therapeutics Development Network (TDN). 

Contact us about VX-445 + tezacaftor + ivacaftor >